News & Media:Insights & News
- Letter to the Duchenne Community: Preliminary Data and Intention to Dose Escalate in IGNITE DMD, February 7, 2019
- Clear To Resume IGNITE DMD, June 18, 2018
- Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial, April 18, 2018
- Letter to the Duchenne Community About the Status of the IGNITE DMD Clinical Trial, March 14, 2018
- Solid Honors Rare Disease Day 2018, February 28, 2018
- Solid Biosciences Initiates Clinical Trial for Gene Transfer Candidate SGT-001 in Patients with Duchenne Muscular Dystrophy, November 30, 2017
- Letter To Duchenne Community About Solid’s First Clinical Trial, November 30, 2017
- Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences, September 20, 2017
- Publication: Gene Transfer Corrects Severe Muscle Defects in Mice with Duchenne Muscular Dystrophy, July 27, 2017
- Advancing Toward the Clinic, June 8, 2017
- New Grant Funding from Save Our Sons and Join Our Boys, June 8, 2017
- Solid Biosciences Strengthens Leadership Team to Advance Programs For Duchenne Muscular Dystrophy, June 7, 2017
- New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy, May 11, 2017
- Solid Biosciences Raises Up To $50 Million In Series C Financing, March 30, 2017
- Solid Honors Rare Disease Day 2017, March 14, 2017
- Steps Forward For Duchenne Muscular Dystrophy, January 30, 2017
- Duchenne Research Fund Provides Grant To Solid For Novel DMD Work, January 30, 2017
- Solid Adds Simvastatin Research Program To Therapeutic Pipeline, November 10, 2016
- Solid Biosciences Granted U.S. and E.U. Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy, October 24, 2016